遗传性溶血性贫血中促红细胞生成素、成纤维细胞生长因子23与红铁酮的相互作用
该研究在90例遗传性溶血性贫血患者中探讨了EPO-FGF23信号通路及红铁酮(ERFE)水平。结果显示总FGF23与EPO水平明显相关(r=+0.64),且校正铁负荷、炎症和肾功能后仍持续;EPO与ERFE也相关(r=+0.47),但ERFE与FGF23无关联,提示ERFE不参与FGF23与EPO的联系。
要点
- 遗传性溶血性贫血中总FGF23与EPO水平呈正相关(r=+0.64)。
- EPO与ERFE相关(r=+0.47),但ERFE与总FGF23或iFGF23无关联。
- EPO-FGF23信号通路可能成为改善无效造血的新靶点。
核心结论
- 首次在遗传性溶血性贫血中证实EPO-FGF23信号通路的重要性,总FGF23与EPO相关而iFGF23与EPO无关,数据符合低i:cFGF23比值。
研究设计与样本
- 研究纳入90例遗传性溶血性贫血患者,注册号NL5189,检测EPO、FGF23(总、iFGF23、cFGF23)及ERFE水平。
主要发现
- 总FGF23与EPO水平明显相关(r=+0.64;95%CI 0.09-0.89),校正铁负荷、炎症和肾功能后仍持续。
- iFGF23与EPO无相关性,数据符合低i:cFGF23比值。
- EPO与ERFE在不同类型遗传性溶血性贫血中相关(r=+0.47;95%CI 0.14-0.69)。
- ERFE与总FGF23或iFGF23无关联,提示ERFE不参与FGF23与EPO的联系。
临床怎么用
- EPO-FGF23信号通路可能为改善遗传性溶血性贫血的无效造血及疾病并发症提供潜在可药物靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recently, erythropoietin (EPO) was identified as regulator of fibroblast growth factor 23 (FGF23). Proteolytic cleavage of biologically active intact FGF23 (iFGF23) results in the formation of C-terminal fragments (cFGF23). An increase in cFGF23 relative to iFGF23 suppresses FGF receptor signaling by competitive inhibition. EPO lowers the i:cFGF23 ratio, thereby overcoming iFGF23-mediated suppression of erythropoiesis. We investigated EPO-FGF23 signaling and levels of erythroferrone (ERFE) in 90 patients with hereditary hemolytic anemia (www.trialregister.nl [NL5189]). We show, for the first time, the importance of EPO-FGF23 signaling in hereditary hemolytic anemia: there was a clear correlation between total FGF23 and EPO levels (r = +0.64; 95% confidence interval [CI], 0.09-0.89), which persisted after adjustment for iron load, inflammation, and kidney function. There was no correlation between iFGF23 and EPO. Data are consistent with a low i:cFGF23 ratio. Therefore, as expected, we report a correlation between EPO and ERFE in a diverse set of hereditary hemolytic anemias (r = +0.47; 95% CI, 0.14-0.69). There was no association between ERFE and total FGF23 or iFGF23, which suggests that ERFE does not contribute to the connection between FGF23 and EPO. These findings open a new area of research and might provide potentially new druggable targets with the opportunity to ameliorate ineffective erythropoiesis and the development of disease complications in hereditary hemolytic anemias.
引用
- van Vuren AJ, Eisenga MF, van Straaten S, et al. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Adv. 2020. PMID: 32324886. doi:10.1182/bloodadvances.2020001595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。